在加纳和肯尼亚5-17月龄儿童中按不同全程、分次及延迟第三剂或早期第四剂方案接种RTS,S/AS01E疟疾疫苗的疗效:一项开放标签、2b期、随机对照试验
该开放标签2b期随机对照试验在加纳和肯尼亚纳入5-17月龄儿童,比较不同全程、分次及延迟第三剂或早期第四剂RTS,S/AS01E方案与狂犬病对照疫苗。结果显示,第三剂后12个月内Fx012-14组相对R012-14和R012-20合并组的增量疫苗效力为-21%(95%CI -57至7;p=0.15),分次方案未优于标准方案;所有RTS,S/AS01E方案均提供实质且相似的临床疟疾保护,未观察到安全性信号。
要点
- Fx012-14组相对R012-14和R012-20合并组的增量疫苗效力为-21%(95%CI -57至7;p=0.15)。
- 截至第21个月,各RTS,S/AS01E组严重不良事件发生率16%、15%、15%、20%,对照组24%,无安全性信号。
- 所有RTS,S/AS01E方案均提供实质且相似的临床疟疾保护,分次方案未优于标准方案。
核心结论
- 第三剂后12个月内,Fx012-14方案未优于标准方案。
- 所有RTS,S/AS01E方案均提供实质且相似的临床疟疾保护,提示推荐给药方案和程序可能具有灵活性。
- 上述结论及年度加强免疫的效果将通过50个月随访进一步评估。
研究设计与样本
- 开放标签、2b期、随机对照试验,在加纳阿散蒂地区阿戈戈疟疾研究中心和肯尼亚西亚亚郡肯尼亚医学研究所与美国疾病控制与预防中心站点开展。
- 纳入5-17月龄、无严重急性或慢性疾病、既往接种过三剂百白破和乙肝疫苗及至少三剂口服脊灰疫苗的儿童。
- 采用基于网络的随机化系统按1:1:1:1:1随机分组,最小化程序考虑中心。
- 2017年9月28日至2018年9月25日入组2157名儿童,其中1609名随机分配至治疗组(每个RTS,S/AS01E组322名,狂犬病疫苗对照组321名)。
- 1500名儿童接受至少一剂研究疫苗,符合方案集包含1332名儿童。
主要发现
- 第三剂后12个月内,Fx012-14组相对R012-14和R012-20合并组的增量疫苗效力为-21%(95%CI -57至7;p=0.15)。
- 截至第21个月,严重不良事件在R012-20组298名儿童中发生48例(16%),R012-14组294名中45例(15%),Fx012-14组304名中47例(15%),Fx017-20组311名中62例(20%),对照组293名中71例(24%),未观察到安全性信号。
关键数值与推荐
- 主要结局为符合方案集中Fx012-14组相对R012-14和R012-20合并组从第2.5个月至第14个月的临床疟疾发生情况。
- 分次剂量为全剂量RTS,S(0.5 mL)复溶后五分之一(0.1 mL)。
- 所有疫苗均经左三角肌肌内注射。
临床怎么用
- 作者认为所有RTS,S/AS01E方案均提供实质且相似的临床疟疾保护,提示推荐给药方案和程序可能具有灵活性。
- 作者指出上述结论及年度加强免疫的效果将通过50个月随访进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Controlled infection studies in malaria-naive adults suggest increased vaccine efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first results of an ongoing trial assessing different fractional-dose regimens in children, in natural exposure settings. METHODS: This open-label, phase 2b, randomised controlled trial is conducted at the Malaria Research Center, Agogo, Ashanti Region (Ghana), and the Kenya Medical Research Institute and the US Centers for Disease Control and Prevention site in Siaya County (Kenya). We enrolled children aged 5-17 months without serious acute or chronic illness who had previously received three doses of diphtheria, tetanus, pertussis, and hepatitis B vaccine and at least three doses of oral polio vaccine. Children were randomly assigned (1:1:1:1:1) using a web-based randomisation system with a minimisation procedure accounting for centre to receive rabies control vaccine (M012 schedule) or two full doses of RTS,S/AS01E at month 0 and month 1, followed by either full doses at months 2 and 20 (group R012-20 [standard regimen]), full doses at months 2, 14, 26, and 38 (R012-14), fractional doses at months 2, 14, 26, and 38 (Fx012-14), or fractional doses at months 7, 20, and 32 (Fx017-20). The fractional doses were administered as one fifth (0·1 mL) of the full RTS,S dose (0·5 mL) after reconstitution. All vaccines were administered by intramuscular injection in the left deltoid. The primary outcome was occurrence of clinical malaria cases from month 2·5 until month 14 for the Fx012-14 group versus the pooled R012-14 and R012-20 groups in the per-protocol set. We assessed incremental vaccine efficacy of the Fx012-14 group versus the pooled R012-14 and R012-20 group over 12 months after dose three. Safety was assessed in all children who received at least one vaccine dose. This trial is registered with ClinicalTrials.gov, NCT03276962. FINDINGS: Between Sept 28, 2017, and Sept 25, 2018, 2157 children were enrolled, of whom 1609 were randomly assigned to a treatment group (322 to each RTS,S/AS01E group and 321 to the rabies vaccine control group). 1500 children received at least one study vaccine dose and the per-protocol set comprised 1332 children. Over 12 months after dose three, the incremental vaccine efficacy in the Fx012-14 group versus the pooled R012-14 and R12-20 groups was -21% (95% CI -57 to 7; p=0·15). Up to month 21, serious adverse events occurred in 48 (16%) of 298 children in the R012-20 group, 45 (15%) of 294 in the R012-14 group, 47 (15%) of 304 in the Fx012-14 group, 62 (20%) of 311 in the Fx017-20 group, and 71 (24%) of 293 in the control group, with no safety signals observed. INTERPRETATION: The Fx012-14 regimen was not superior to the standard regimen over 12 months after dose three. All RTS,S/AS01E regimens provided substantial, similar protection against clinical malaria, suggesting potential flexibility in the recommended dosing regimen and schedule. This, and the effect of annual boosters, will be further evaluated through 50 months of follow-up. FUNDING: GlaxoSmithKline Biologicals; PATH's Malaria Vaccine Initiative.
引用
- Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. Lancet Infect Dis. 2022. PMID: 35753316. doi:10.1016/S1473-3099(22)00273-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。